1. Virometix
  2. Pipeline

Our Pipeline

  1. Virometix
  2. Pipeline

Our Pipeline

Our technology platform lends itself to a wide range of applications.

We are developing a portfolio of products highlighted by a first-in-class vaccine for Respiratory Syncytial Virus (RSV), serotype-independent vaccine candidate against Streptococcus pneumoniae and Coronaviruses prophylactic approaches.

To further advance our platform and offer tangible solutions to health conditions, we welcome collaboration opportunities and various partnering options.

Detailed Vaccine Programs

Universal Pneumococcal Vaccine

  • Rationale: Infections caused by Streptococcus pneumoniae result in significant morbidity and mortality. Conventional polysaccharide or conjugated vaccines induce serotype-specific antibodies, limiting clinical effectiveness. The emergence of new bacterial serotypes reduces long-term efficacy.
  • Virometix is developing a first-in-class serotype-independent vaccine candidate against Streptococcus pneumoniae RSV Vaccine
  • RSV is a prevalent, contagious respiratory pathogen and a leading cause of bronchitis and pneumonia globally. It affects over 64 million people annually.
  • Particularly risky for vulnerable groups (infants, elderly) — significant morbidity and mortality potential.
  • With candidate “V-306”, Virometix uses a neutralizing epitope on RSV-F protein displayed on synthetic Virus-Like Particles (SVLPs).
  • In the Phase I trial (NCT04519073), the vaccine was found to be safe, well-tolerated, and immunogenic.

Platform Potential in Cancer

Virometix’s synthetic nanoparticle vaccine platform, based on its proprietary Synthetic Virus-Like Particle (SVLP) technology, holds significant potential for cancer immunotherapy. The SVLP platform uses self-assembling lipopeptidic nanoparticles that display synthetic peptide mimetics, including built-in adjuvants like T-helper epitopes and Toll-like receptor (TLR) ligands, which eliminate the need for biological components and simplify manufacturing. This modular, flexible design, combined with its self-adjuvant properties and immune activation capabilities, allows for targeted and robust immune responses. In the context of cancer, SVLPs displaying cancer-specific antigens are engineered to effectively present these antigens to the immune system, stimulating cytotoxic T-cell activation both in vitro and in vivo. Virometix is exploring various strategies to optimize these particle-based vaccines as part of its effort to develop best-in-class therapeutic solutions for cancer.